Skip to main content
OpenTrials
Completed

NCT Number: NCT00506974

Enhancing Slow Wave Sleep With Sodium Oxybate

The purpose of this study is to determine if there the impact of sleep deprivation upon sleepiness, attention, memory, and mood is reduced by pharmacologically enhancing slow wave sleep (SWS) with sodium oxybate.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Sleep Medicine and Research Center at St. Luke's Hospital

Chesterfield, Missouri, 63017, United States

About this study

SWS has been hypothesized to be a time of relatively high neural recuperation from wakefulness. That hypothesis has been prompted by a number of observations, including: 1) enhanced SWS following sleep deprivation in proportion to the duration of prior wakefulness, 2) reduced amounts of SWS during nocturnal sleep following afternoon/evening naps, 3) a gradual decline in SWS across a night of sleep, and 4) increased SWS following nights of fragmented sleep. Within the two-process model of sleep regulation, heightened SWS has been viewed as reflecting Process S, the homeostatic component. Many authors have proposed that increased SWS represents ongoing cortical recovery from prior wakefulness activities and is a time of relatively heightened neurophysiologic restoration or recuperation. In a prior study which we conducted (Walsh et al., 1994) there was a suggestion, from post hoc analyses, that SWS may prevent adverse effects of sleep loss. Additionally, we recently published the results of an investigation of pharmacologically-enhanced SWS (with tiagabine) during sleep restriction which demonstrated preserved neurobehavioral performance despite sleep restriction (Walsh et al, 2006). In the proposed research we will examine whether pharmacological enhancement of SWS with sodium oxybate reduces the impact of sleep deprivation upon sleepiness, attention, performance, mood, and autonomic nervous system activity.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • males and females, ages 18-50 inclusive
  • use of adequate contraceptive procedures throughout the study for females.

Exclusion criteria

  • pregnancy or lactating
  • prior use of or allergy to sodium oxybate
  • participation in a clinical research trial within the past 30 days
  • blood donation within the past 30 days

Treatment and study plan

Sodium Oxybate

Drug

3.5 g of sodium oxybate or placebo on two of the five overnights.

Other names: xyrem

Primary outcomes

  1. MSLT

    Time frame: throughout the study

  2. PVT

    Time frame: throughout the study

Sponsors and collaborators

Lead sponsor

St. Luke's Hospital, Chesterfield, Missouri

Other

Collaborators

  • Jazz Pharmaceuticals

Registry information

Official study title

Enhancing Slow Wave Sleep With Sodium Oxybate to Reduce the Behavioral and Physiological Impact of Sleep Loss

Important dates

Study start
2007
Primary completion
2008
Study completion
2008
First posted
Jul 25, 2007
Registry last updated
Sep 26, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.